Compared with non-demented controls, neuronal BRCA1
levels in the patients were reduced by 65-75%.
A small percentage of patients (about 5%) who undergo genetic testing for BRCA1
and BRCA2 receive a variant of uncertain significance (VUS) result, indicating a genetic sequence change with an unknown association with cancer risk.
Why do non-Jews in the Southwest have BRCA1
and BRCA2 gene mutations?
modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells.
The pedigrees of these three groups of families were compared to determine the respective contribution of BRCA1
and BRCA2 to breast and ovarian cancer and to establish which other cancers may be associated with mutations in these genes.
We report the identification and characterization of allele-specific splicing (ASS) linked to the nonpathogenic BRCA1
As we shall see, histology is also of utmost importance in driving the decision to test for BRCA1
Attempts to adjust for ascertainment bias has resulted in lower overall risks being estimated for BRCA1
and BRCA2 , especially when these studies include population-based series .
protein in mammary tumours of rats fed marine omega- 3 fatty acids.
A paper in the 15 August 2006 issue of Cancer Research now gives the clearest picture to date of how many people in the United States carry mutations in the two dominant "breast cancer genes," BRCA1
Carriers of BRCA1
or BRCA2 gene mutations have an increased risk of ovarian cancer, cancer of the fallopian tubes, and primary peritoneal cancer.
(omi4) sequence is used for identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because the patient has an inherited causative mutation in their BRCA1